A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
Commentary|Podcasts|October 17, 2023
Pharmacy Focus: Oncology Edition- A Practical, Real-World Understanding of the Enhancing Oncology Model
The updated version of the Oncology Care Model (OCM) incentivizes value-based care over volume, but some wonder if it is enough.
Advertisement
This month, we spoke with Bobby Green, MD, President and Chief Medical Officer at Thyme Care, Nashville, Tennessee. Green walks pharmacists through one of the most impactful payment models in oncology today, providing a natural break down of the enhancing oncology model (EOM) and how it works for patients and health care providers in Medicare and Medicaid.
Advertisement
Related to this article
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
IRAKLIA data show that isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion rates.
Gut microbiome disruption from antianaerobic antibiotics weakens CAR T-cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
The all-oral combination is supported by phase 3 LITESPARK-011 data showing improved progression-free survival compared with cabozantinib.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
4
Expert Q&A: Researcher Urges Autonomic Assessment for Patients With Long COVID
5